Bram Boeckx
Overview
Explore the profile of Bram Boeckx including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
5336
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Metoikidou C, Karnaukhov V, Boeckx B, Timperi E, Bonte P, Wang L, et al.
Cell Rep Med
. 2025 Feb;
:101973.
PMID: 39983715
Chemotherapy combined with immune checkpoint blockade has shown clinical activity in breast cancer. Response, however, occurs in only a low proportion of patients. How the immune landscape of the tumor...
2.
Jirstrom E, Matveeva A, Baindoor S, Donovan P, Ma Q, Morrissey E, et al.
Exp Neurol
. 2024 Dec;
385:115128.
PMID: 39719207
tRNA-derived stress-induced RNAs (tiRNAs) are a new class of small non-coding RNA that have emerged as important regulators of cellular stress responses. tiRNAs are derived from specific tRNA cleavage by...
3.
Nederlof I, Isaeva O, de Graaf M, Gielen R, Bakker N, Rolfes A, et al.
Nat Med
. 2024 Sep;
30(11):3223-3235.
PMID: 39284953
Immune checkpoint inhibition (ICI) with chemotherapy is now the standard of care for stage II-III triple-negative breast cancer; however, it is largely unknown for which patients ICI without chemotherapy could...
4.
Kinget L, Naulaerts S, Govaerts J, Vanmeerbeek I, Sprooten J, Laureano R, et al.
Nat Med
. 2024 Jul;
30(8):2375-2376.
PMID: 39009782
No abstract available.
5.
Declercq M, Treps L, Geldhof V, Conchinha N, de Rooij L, Subramanian A, et al.
Liver Int
. 2024 Jun;
44(9):2382-2395.
PMID: 38847551
Background & Aims: Cystic fibrosis (CF) is considered a multisystemic disorder in which CF-associated liver disease (CFLD) is the third most common cause of mortality. Currently, no effective treatment is...
6.
Kinget L, Naulaerts S, Govaerts J, Vanmeerbeek I, Sprooten J, Laureano R, et al.
Nat Med
. 2024 May;
30(6):1667-1679.
PMID: 38773341
An important challenge in the real-world management of patients with advanced clear-cell renal cell carcinoma (aRCC) is determining who might benefit from immune checkpoint blockade (ICB). Here we performed a...
7.
Feio-Azevedo R, Boesch M, Radenkovic S, van Melkebeke L, Smets L, Wallays M, et al.
Hepatology
. 2024 May;
81(2):509-522.
PMID: 38761406
Background And Aims: Acute-on-chronic liver failure (ACLF) is a complication of cirrhosis characterized by multiple organ failure and high short-term mortality. The pathophysiology of ACLF involves elevated systemic inflammation leading...
8.
De Wispelaere W, Annibali D, Tuyaerts S, Messiaen J, Antoranz A, Shankar G, et al.
Clin Transl Med
. 2024 May;
14(5):e1655.
PMID: 38711203
Background: Uterine leiomyosarcomas (uLMS) are aggressive tumours with poor prognosis and limited treatment options. Although immune checkpoint blockade (ICB) has proven effective in some 'challenging-to-treat' cancers, clinical trials showed that...
9.
Geukens T, De Schepper M, Van Den Bogaert W, Van Baelen K, Maetens M, Pabba A, et al.
NPJ Breast Cancer
. 2024 Apr;
10(1):31.
PMID: 38658604
Research on metastatic cancer has been hampered by limited sample availability. Here we present the breast cancer post-mortem tissue donation program UPTIDER and show how it enabled sampling of a...
10.
Turpin R, Liu R, Munne P, Peura A, Rannikko J, Philips G, et al.
J Immunother Cancer
. 2024 Apr;
12(4).
PMID: 38604809
Background: Combining cytotoxic chemotherapy or novel anticancer drugs with T-cell modulators holds great promise in treating advanced cancers. However, the response varies depending on the tumor immune microenvironment (TIME). Therefore,...